Table 1 Mice used in pre- and post-treatment experiments.

From: Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy

Numbers of adult CD1 mice

Pre-treatment

Post-treatment

Groups

IHC

WB

Groups

IHC/FJC

WB

EB

EEG

Vehicle

12

8

Pilocarpine

24

45

39

29

IVIg

13

7

SE mice

16

19

20

18

Vehicle SE

7

5

Vehicle

8

9

11

5

(21.8 ± 1.6)

(21.6 ± 2.2)

(20.6 ± 1.8)

(21.5 ± 2.8)

IVIg SE

4

4

IVIg

8

10

9

7

(21.0 ± 2.5)

(20.7 ± 1.3)

(21.9 ± 3.4)

(24.2 ± 3.1)

  1. In pre-treatment experiments, mice were randomly allocated to receive vehicle or IVIg before administration of pilocarpine. Animals developing SE were used for immunohistochemistry (IHC), Fluoro Jade C staining (FJC) and western blotting (WB) studies, as shown in the bottom two rows.
  2. In post-treatment experiments, mice developing SE were randomly allocated to receive vehicle or IVIg. The number of animals receiving pilocarpine (Post-treatment, Row 1), the number developing SE (Row 2) are shown. The number of animals receiving vehicle or IVIg used for IHC, WB, Evans blue staining (EB) and electroencephalography (EEG) are shown in Rows 3 and 4. The numbers in brackets are the seizure scores of each group (modified Racine scale, mean ± standard error of the mean, no significant difference between SE vehicle and SE IVIg groups, unpaired t-test). Fewer animals underwent EEG recording than were randomised due to the death of 3 vehicle-treated and 3 IVIg-treated animals before EEG recording.
Back to article page